1 hour ago
Merck (MRK) Shares Climb 3% Following FDA Priority Review for KEYTRUDA Bladder Cancer Treatment
Merck (MRK) stock climbed 3% after FDA granted priority review for KEYTRUDA bladder cancer treatment combination, with decision expected August 17, 2026.
The post Merck (MRK) Shares Climb 3% Following FDA Priority Review for KEYTRUDA Bladder Cancer Treatment appeared first on Blockonomi.
Source: Blockonomi →Related News
- 31 minutes ago
Nike Stock at Decade Low as Insider Buying Signals Possible Bottom
- 37 minutes ago
Netflix (NFLX) Stock Plunges 10% as Ark Invest’s Cathie Wood Doubles Down
- 50 minutes ago
Psychedelic Drug Stocks Explode After Trump’s FDA Fast-Track Executive Order
- 50 minutes ago
Vertical Aerospace (EVTL) Stock Tumbles 10% Following $850M Capital Raise Announ...
- 51 minutes ago
Morgan Stanley: Memory Makers Micron and Sandisk Trump Intel (INTC) and AMD for...